MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

MacroGenics Inc

Aperta

SettoreSettore sanitario

1.76 4.14

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.7

Massimo

1.82

Metriche Chiave

By Trading Economics

Entrata

4.8M

-36M

Vendite

9M

22M

Margine di Profitto

-162.992

Dipendenti

341

EBITDA

5.7M

-33M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+113.07% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

18M

111M

Apertura precedente

-2.38

Chiusura precedente

1.76

Notizie sul Sentiment di mercato

By Acuity

27%

73%

86 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

MacroGenics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 ott 2025, 16:58 UTC

Utili

BMW Trims 2025 View, Citing Weaker Performance in China

7 ott 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 ott 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 ott 2025, 23:19 UTC

Discorsi di Mercato

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 22:50 UTC

Discorsi di Mercato

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 ott 2025, 22:40 UTC

Discorsi di Mercato

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

7 ott 2025, 21:56 UTC

Discorsi di Mercato

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 20:44 UTC

Azioni calde

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 ott 2025, 19:42 UTC

Discorsi di Mercato

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 ott 2025, 19:23 UTC

Acquisizioni, Fusioni, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 ott 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 ott 2025, 19:02 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

7 ott 2025, 16:20 UTC

Discorsi di Mercato

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 ott 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 15:37 UTC

Discorsi di Mercato

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 ott 2025, 15:33 UTC

Discorsi di Mercato

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 ott 2025, 15:25 UTC

Discorsi di Mercato

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 ott 2025, 15:15 UTC

Discorsi di Mercato

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

7 ott 2025, 15:04 UTC

Discorsi di Mercato

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 ott 2025, 14:56 UTC

Discorsi di Mercato

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 ott 2025, 14:52 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

MacroGenics Inc Previsione

Obiettivo di Prezzo

By TipRanks

113.07% in crescita

Previsioni per 12 mesi

Media 3.75 USD  113.07%

Alto 5 USD

Basso 3 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per MacroGenics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

3

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.47 / 1.64Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

86 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat